Yakup Ergün· @dr_yakupergun · X·· 1 天前评分70
正文 · 原文
#ESMO26 | SAFFRON
Targeting MET-driven resistance after osimertinib with an all-oral, chemo-free regimen delivers both PFS and OS benefits. A nearly 5-month improvement in median OS reinforces its clinical value.
Identifying the resistance mechanism at progression matters! However, where osimertinib + savolitinib fits relative to amivantamab + chemo remains an open question.
66 浏览 · 0 赞 · 0 转发 · 0 回复
#ESMO26 | SAFFRON | Presidential Session-2 In EGFR-mutant, MET-overexpressed/amplified advanced NSCLC after osimertinib: Osimertinib + savolitinib vs platinum-pemetrexed: 🔹 PFS: 7.6 vs 5.4 mo (HR 0.55) 🔹 OS: 17.8 vs 12.9 mo(HR 0.68)在 X 查看被引用的帖子
来源：Yakup Ergün · x.com